

James F Donohue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4521133/publications.pdf>

Version: 2024-02-01

87
papers

4,029
citations

172457

29
h-index

118850

62
g-index

94
all docs

94
docs citations

94
times ranked

2597
citing authors

#	ARTICLE	IF	CITATIONS
1	Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD. <i>Pulmonary Therapy</i> , 2021, 7, 47-57.	2.2	3
2	Acclidinium bromide/formoterol fumarate as a treatment for COPD: an update. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1093-1106.	2.5	3
3	Future concepts in bronchodilation for COPD: dual- versus mono-therapy. <i>European Respiratory Review</i> , 2021, 30, 210023.	7.1	7
4	Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis. <i>BMC Pulmonary Medicine</i> , 2020, 20, 134.	2.0	2
5	Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662090527.	2.6	3
6	<p>The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 745-754.	2.3	1
7	Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). <i>Respiratory Research</i> , 2019, 20, 241.	3.6	11
8	Use of a Cross-Sectional Survey in the Adult Population to Characterize Persons at High-Risk for Chronic Obstructive Pulmonary Disease. <i>Healthcare (Switzerland)</i> , 2019, 7, 12.	2.0	1
9	Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 57, 101808.	2.6	11
10	Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2019, 153, 38-43.	2.9	25
11	Acclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661985072.	2.6	4
12	<p>Efficacy of acclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 479-491.	2.3	7
13	<p>Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 585-595.	2.3	48
14	Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. <i>Pulmonary Therapy</i> , 2019, 5, 23-41.	2.2	7
15	<p>Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2947-2958.	2.3	6
16	<p>An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2835-2848.	2.3	16
17	Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2019, 32, 24-33.	1.4	5
18	The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 341-349.	0.7	16

#	ARTICLE	IF	CITATIONS
19	Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 11-19.	2.6	41
20	An Update on the Global Initiative for Chronic Obstructive Lung Disease 2017 Guidelines With a Focus on Classification and Management of Stable COPD. <i>Respiratory Care</i> , 2018, 63, 749-758.	1.6	19
21	Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. <i>International Journal of COPD</i> , 2018, Volume 13, 499-508.	2.3	3
22	Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018, 5, 193-207.	0.7	3
23	Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year. <i>Clinical Therapeutics</i> , 2017, 39, 66-74.	2.5	3
24	A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension [®] , [®] Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2017, 18, 8.	3.6	21
25	A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2017, 125, 39-48.	2.9	28
26	Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension [®] , [®] Delivery Technology in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2017, 126, 105-115.	2.9	63
27	Efficacy and safety of glycopyrrolate/eFlow [®] CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. <i>Respiratory Medicine</i> , 2017, 132, 238-250.	2.9	36
28	Improving the Management of COPD in Women. <i>Chest</i> , 2017, 151, 686-696.	0.8	86
29	Comparative efficacy of long-acting β_2 -agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. <i>International Journal of COPD</i> , 2017, Volume 12, 367-381.	2.3	25
30	Dose selection for glycopyrrolate/eFlow [®] phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies. <i>Respiratory Research</i> , 2017, 18, 202.	3.6	7
31	Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. <i>International Journal of COPD</i> , 2016, 11, 785.	2.3	19
32	Response to Letter to the Editor: Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. <i>Respiratory Medicine</i> , 2016, 110, 81.	2.9	1
33	The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis. <i>Respiratory Research</i> , 2016, 17, 40.	3.6	32
34	Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD. <i>Respiratory Medicine</i> , 2016, 116, 41-48.	2.9	29
35	A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. <i>Respiratory Medicine</i> , 2016, 120, 16-24.	2.9	18
36	Another Choice for Prevention of COPD Exacerbations. <i>New England Journal of Medicine</i> , 2016, 374, 2284-2286.	27.0	7

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. <i>BMC Pulmonary Medicine</i> , 2016, 16, 65.	2.0	18
38	Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis. <i>Drugs</i> , 2016, 76, 343-361.	10.9	22
39	Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. <i>Respiratory Medicine</i> , 2016, 112, 65-74.	2.9	57
40	Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 463-472.	2.4	8
41	Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 317-324.	2.4	1
42	Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial. <i>BMJ Open</i> , 2015, 5, e006131-e006131.	1.9	21
43	Correlation of PROMIS scales and clinical measures among chronic obstructive pulmonary disease patients with and without exacerbations. <i>Quality of Life Research</i> , 2015, 24, 999-1009.	3.1	20
44	A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1845-1860.	1.8	30
45	Indacaterol vs tiotropium in COPD patients classified as GOLD A and B. <i>Respiratory Medicine</i> , 2015, 109, 1031-1039.	2.9	10
46	The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 101-108.	2.6	8
47	Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. <i>Respiratory Medicine</i> , 2015, 109, 870-881.	2.9	77
48	Low Doses of Long-Acting β_2 -Agonists/Long-Acting Muscarinic Agents with Large Effects. The FLIGHT Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1028-1030.	5.6	4
49	Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 519-532.	2.5	6
50	Considerations for managing chronic obstructive pulmonary disease in the elderly. <i>Clinical Interventions in Aging</i> , 2014, 9, 23.	2.9	64
51	Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study. <i>International Journal of COPD</i> , 2014, 9, 745.	2.3	47
52	Systematic review comparing LABA, olodaterol, and indacaterol: limitations. <i>International Journal of COPD</i> , 2014, 9, 1331.	2.3	2
53	Dose response of umeclidinium administered once or twice daily in patients with COPD: A pooled analysis of two randomized, double-blind, placebo-controlled studies. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1214-1220.	2.0	13
54	Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. <i>Respiratory Research</i> , 2014, 15, 78.	3.6	84

#	ARTICLE	IF	CITATIONS
55	A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. <i>Respiratory Medicine</i> , 2014, 108, 1310-1320.	2.9	12
56	One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD. <i>Chest</i> , 2014, 146, 1531-1542.	0.8	22
57	Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates. <i>Respiratory Medicine</i> , 2013, 107, 943-952.	2.9	80
58	Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis. <i>Respiratory Research</i> , 2013, 14, 100.	3.6	60
59	Population-Based Burden of COPD-Related Visits in the ED. <i>Chest</i> , 2013, 144, 784-793.	0.8	26
60	A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. <i>Respiratory Medicine</i> , 2012, 106, 970-979.	2.9	60
61	Optimum Bronchodilator Combinations in Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , 2012, 72, 301-308.	10.9	10
62	Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. <i>Respiratory Research</i> , 2012, 13, 52.	3.6	18
63	Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2011, 6, 35.	2.3	5
64	Safety of indacaterol in the treatment of patients with COPD. <i>International Journal of COPD</i> , 2011, 6, 477.	2.3	53
65	Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. <i>Respiratory Research</i> , 2011, 12, 161.	3.6	66
66	Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2011, 12, 55.	3.6	70
67	The Safety and Efficacy of Arformoterol and Formoterol in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 7, 17-31.	1.6	23
68	Bronchodilator Reversibility in COPD. <i>Chest</i> , 2011, 140, 1055-1063.	0.8	80
69	Indacaterol. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 327-328.	1.6	2
70	Nebulized formoterol: a review of clinical efficacy and safety in COPD. <i>International Journal of COPD</i> , 2010, 5, 223.	2.3	8
71	Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 155-162.	5.6	333
72	Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. <i>International Journal of COPD</i> , 2010, 5, 1-10.	2.3	48

#	ARTICLE	IF	CITATIONS
73	Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study. <i>Clinical Therapeutics</i> , 2008, 30, 989-1002.	2.5	21
74	Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 199-208.	2.6	20
75	Safety and efficacy of beta agonists. <i>Respiratory Care</i> , 2008, 53, 618-22; discussion 623-4.	1.6	11
76	Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 526-534.	3.5	63
77	Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects. <i>Proceedings of the American Thoracic Society</i> , 2005, 2, 272-281.	3.5	28
78	Still looking for answers in COPD. <i>Lancet, The</i> , 2005, 365, 1518-1520.	13.7	3
79	Minimal Clinically Important Differences in COPD Lung Function. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 111-124.	1.6	398
80	Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2004, 1, 152-160.	3.5	16
81	A Short-Term Comparison of Fluticasone Propionate/Salmeterol with Ipratropium Bromide/Albuterol for the Treatment of COPD. <i>Treatments in Respiratory Medicine</i> , 2004, 3, 173-181.	1.4	44
82	Therapeutic Responses in Asthma and COPD. <i>Chest</i> , 2004, 126, 125S-137S.	0.8	89
83	A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol. <i>Chest</i> , 2002, 122, 47-55.	0.8	428
84	The Spirometric Efficacy of Once-Daily Dosing With Tiotropium in Stable COPD. <i>Chest</i> , 2000, 118, 1294-1302.	0.8	186
85	Efficacy of Salmeterol Xinafoate in the Treatment of COPD. <i>Chest</i> , 1999, 115, 957-965.	0.8	481
86	Dose Response to Ipratropium as a Nebulized Solution in Patients with Chronic Obstructive Pulmonary Disease: A Three-Center Study. <i>The American Review of Respiratory Disease</i> , 1989, 139, 1188-1191.	2.9	117
87	Ranitidine at very large doses does not inhibit theophylline elimination. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 577-581.	4.7	39